IL-15 trans-presentation can be blocked by targeting the cytokine receptor subunit IL-2/IL-15Rβ, and this is achieved through the use of Hu-Mik-β1 monoclonal antibody which is used now in clinical trials for treating those with autoimmune diseases [18, 19]. Here, IL2RB is linked to autoimmune disease.